Navigation Links
ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
Date:2/25/2008

WELLESLEY HILLS, Mass., Feb. 25 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, as a result of growing interest from prospective buyers, announced today a development strategy for further advancement of the company's proprietary benzoxazinorifamycins as leading antibacterial drug candidates in combination antibiotic therapy. Rifalazil is the most developed of these compounds, though most of the interest for combination antibiotics has centered on novel compounds or new chemical entities ("NCEs").

Combination antibiotic therapy has been used as the treatment of choice for certain stubborn bacterial infections. Two prime examples are tuberculosis and gastric ulcer disease, caused by Mycobacterium tuberculosis infection and Helicobacter pylori infection, respectively. In both of these examples, the rifamycins rifampin and rifabutin have been used because of their potency against these pathogens. However, these rifamycins share the negative attribute of eliciting drug-drug interactions; that is, they interfere with the actions of many other medications that the patient may require. The NCEs are breakthrough drug candidates because they have not been shown preclinically to engender drug-drug interactions caused by the other rifamycins. In addition the NCEs have equal or superior potency compared with rifampin.

There is increasing recognition that rifamycins (e.g. rifampin and ABI- 0043) are highly efficacious against implant-associated staphylococcal infection. This property is due to their excellent efficacy against non- growing and surface-adhering staphylococci. No other class of antimicrobial agents shares this property. In view of the growing number of patients with implants (artificial joints, internal fixation devices, vascular grafts etc.) there is an urgent need for this type of antibiotic. "The development of an NCE for combination antibiotic treatment could be extremely beneficial," commented Werner Zimmerli, M.D., a leading infectious disease clinician and researcher at the University of Basel, Switzerland. "In our animal model for implant-associated infections, which has proven to be clinically predictive of combination antibiotic efficacy for the treatment of foreign body infections, the NCE ABI-0043 was as effective as rifampin. The fact that ABI-0043 is not predicted to have drug-drug interactions provides a very significant advantage over rifampin, which cannot be given, for example, in patients with oral anticoagulation due to dangerous interaction." In addition, based on their antibacterial spectrum and potency against key pathogens, the NCEs may also be developed for the treatment of bacterial endocarditis, osteomyelitis, acute and chronic respiratory infections, gastrointestinal infections, and acne.

The sale of ActivBiotics' assets, including rifalazil and the NCEs, is being conducted through an Assignment for the Benefit of Creditors. The bidding for the assets, which may be purchased separately or in combination, is scheduled for March 14, 2008.

For additional information on the terms of sale and to obtain a bidder's package, please contact Joseph F. Finn, Jr., CPA (jffinnjr@earthlink.net, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. For technical information on the assets, please contact Christo Shalish, cshalish@activbiotics.com.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
2. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
3. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
4. Cancer Cure Coalition Proposes Major Changes at the FDA
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
6. Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
7. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
10. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
11. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... 2017 Endo International plc (NASDAQ: ... Hon. Joseph R. Goodwin , U.S. District Court ... Virginia , entered a case management order in ... Products Liability Litigation (the "MDL") that includes a provision ... expert disclosures on specific causation within one hundred twenty ...
(Date:6/5/2017)... Neb. , June 5, 2017 ... in the United States . ... helps a fallen person up to an almost-standing ... easily assembled and operated by one assistant and does ... It is simple enough that a child can operate ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... insurance management and financial planning assistance to clients in southern Montana, is announcing ... offered by Zoo Montana. , The outreach programs offered by Zoo Montana provide ...
(Date:6/27/2017)... IL (PRWEB) , ... June 27, 2017 , ... ... considering a cosmetic treatment, according to survey data released today by the ... on Cosmetic Dermatologic Procedures indicates the percentage of consumers considering a cosmetic ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... Dermatologic Surgery Association’s SUNucate efforts, Louisiana became the sixth state to pass ... With Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is ... case studies guidebook. This guidebook offers an excellent branding and exposure opportunity for ... case studies and how-to’s that fall into the following categories:, ...
Breaking Medicine News(10 mins):